Bionoxx Inc.
Tuesday, June 04, 2024
Company Presentation
![Oncology](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/BIO-track-icon_Oncology_MTC.png)
Company Presentation Theater 1
Bionoxx Inc. (Bionoxx), founded in 2016, is committed to demystifying the functional heterogeneity of circulating neutrophils in cancer as well as immune-related diseases.
Based on BNX-IFS (Immune Function States), a unique assay that detects activated neutrophils implicated in impaired immune homeostasis, we have shown effective immunomodulatory strategies in the treatment of ICI-resistant tumor mice model and viral sepsis mice model.
Employing this strategy, Bionoxx obtained USFDA acceptance to proceed with a first-in-human trial with Immuno-Oncology (IO) virotherapy (mOTS-400) aimed at overcoming ICI resistance.
BNX-IFS's ability to detect specific immune states in circulating blood is essential for tailoring immunomodulatory strategies across immune-related conditions. BNX is actively seeking partnerships with leading pharmaceutical companies to further our mission and make significant strides in the field of immunotherapy.
![Bionoxx Inc.](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1806753-1-JPG.jpg)
Company Website:
http://www.bionoxx.com
Lead Product in Development:
immuno-oncology therapy
Company HQ City
Seongnam
Company HQ State
Gyeonggi-do
Company HQ Country
Korea, Republic of
CEO/Top Company Official
Soobeum Yi
Development Phase of Primary Product
Phase I
Primary Speaker